Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19420853 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL19410189 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL19410188 | 1.00 | MDM4 (0.53) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL19410124 | 0.87 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL15630864 | 0.77 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL34468451 | 0.77 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL15630865 | 0.77 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL20211701 | 0.77 | MDM4 (0.54) | MDM4TP53MDM2CASP3SLC17A5 | |
| SCHEMBL16059782 | 0.77 | MDM2 (0.55) | MDM4TP53MDM2CASP3 | |
| SCHEMBL46349 | 0.76 | MDM4 (0.55) | MDM4TP53MDM2CASP3SLC17A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3440097-B1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-23 | — | — | EP | disclosed |
| US-10358463-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-07-23 | — | — | US | disclosed |
| EP-3440097-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | Bristol-Myers Squibb Company (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017176608-A1 | MACROCYCLIC INHIBITORS OF THE PD-1/PD-L1 AND CD80/PD-L1 PROTEIN/PROTEIN INTERACTIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170283463-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283463-A1 | IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | MDM4 532/4885TP53 61/4885MDM2 980/4885 |
| US-10358463-B2 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | MDM4 532/4885TP53 61/4885MDM2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.